NCT03991741View on ClinicalTrials.gov

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 7, 2020

Primary Completion Date

January 26, 2023

Study Completion Date

January 26, 2023

Conditions
Metastatic MelanomaLocally Advanced Refractory/Recurrent MelanomaMetastatic Head and Neck CancerLocally Advanced Refractory/Recurrent Head and Neck Cancer
Interventions
BIOLOGICAL

Autologous Tumor Infiltrating Lymphocytes

Autologous TILs

BIOLOGICAL

High-Dose Interleukin 2

720,000 IU/kg every 8 hours for up to 15 doses

Trial Locations (1)

92093

UC San Diego Moores Cancer Center, La Jolla

Sponsors

Lead Sponsor

Gregory Daniels
All Listed Sponsors
collaborator

Immunotherapy Foundation

UNKNOWN

lead

Gregory Daniels

OTHER